Skip to main content

Advertisement

SpringerLink
Log in

RETRACTED ARTICLE: Overexpression of interleukins IL-17 and IL-8 with poor prognosis in colorectal cancer induces metastasis

  • Original Article
  • Published:
Tumor Biology

This article was retracted on 09 November 2016

Abstract

Current evidences indicated that a group of soluble mediators called chemokines is involved in tumor growth and metastasis. The association of IL-8 with tumor cell migration was previously found, and its expression was related to angiogenesis, tumor progression, and metastasis in many kinds of carcinomas in human and animal models. Furthermore, it has been showed that IL-17 plays its role as either a proteome of tumor progression or antitumor indifferent cancer models. To investigate the messenger RNA (mRNA) expressions of IL-8 and IL-17 in patients with colorectal cancer (CRC) and non-tumor tissue, quantitative real-time PCR was used in the study. Our results showed that expression of IL-8 mRNA was significantly increased in tumor tissues (mean ± SD 3.84 ± 0.08) compared with adjacent normal mucosa (mean ± SD 1.17 ± 0.75, P = 0.001). Furthermore, a higher expression of IL-17 mRNA was found in tumor tissues (mean ± SD 2.73 ± 0.69) when compared with normal tissues (mean ± SD 1.06 ± 0.07, P = 0.001). Our findings indicated that advanced tumor-node-metastasis (TNM) stage (P = 0.024) and histological grade (poorly differentiated, P = 0.013) and distant metastasis (P = 0.001) were correlated with expression of IL-8. Moreover, high expression of IL-17 showed significant association with early stage CRC (TNM) (P = 0.038). In conclusion, the expression of IL-8 and IL-17 mRNAs was significantly increased in tumor tissues compared with adjacent normal tissues. We found that advanced TNM stage and histological grade and distant metastasis were correlated with expression of IL-8, while high expression of IL-17 showed significant association with early stage CRC (TNM) stage and overexpression of IL-8 may be associated with progression of CRC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Tan E, Tilney H, Thompson M, Smith J, Tekkis PP. Association of coloproctology of Great Britain and Ireland, The United Kingdom national bowel cancer project—epidemiology and surgical risk in the elderly. Eur J Cancer. 2007;43:2285–94.

    Article  PubMed  Google Scholar 

  2. Ries LAG, Eisner MP. SEER cancer statistics review, 1973–1997. Bethesda: National Cancer Institute; 2000.

    Google Scholar 

  3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.

    Article  PubMed  Google Scholar 

  4. Doll D, Keller L, Maak M, Boulesteix AL, Siewert JR, Holzmann B. Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival. Int J Color Dis. 2010;25(5):573–81.

    Article  Google Scholar 

  5. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell. 2004;6:447–58.

    Article  CAS  PubMed  Google Scholar 

  6. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010;70:1063–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol. 2000;18:217–42.

    Article  CAS  PubMed  Google Scholar 

  8. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res. 2000;6:2104–19.

    CAS  PubMed  Google Scholar 

  9. Zhu YM, Webster SJ, Flower D, Woll PJ. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer. 2004;91:1970–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kitadai Y, Haruma K, Mukaida N, Ohmoto Y, Matsutani N, Yasui W, et al. Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. Clin Cancer Res. 2000;6:2735–40.

    CAS  PubMed  Google Scholar 

  11. Maeda S, Omata M. Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci. 2008;99(5):836–42.

    Article  CAS  PubMed  Google Scholar 

  12. Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008;267(2):226–44.

    Article  CAS  PubMed  Google Scholar 

  13. Masuya D, Huang C, Liu D, Kameyama K, Hayashi E, Yamauchi A. The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer. 2001;92(10):2628–38.

    Article  CAS  PubMed  Google Scholar 

  14. Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002;161(1):125–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Cui G, Yuan A, Goll R, Florholmen J. IL-17A in the tumor microenvironment of the human colorectal adenoma–carcinoma sequence. Scand J Gastroenterol. 2012;47:1304–12.

    Article  CAS  PubMed  Google Scholar 

  16. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 2009;50:980–9.

    Article  CAS  PubMed  Google Scholar 

  17. He D, Li H, Yusuf N, Elmets CA, Li J, Mountz JD. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol. 2010;184:2281–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009;31:787–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood. 2009;114:357–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Takamori H, Oades ZG, Hoch OC, Burger M, Schraufstatter IU. Autocrine growth effect of IL-8 and GROalpha on a human pancreatic cancer cell line, capan-1. Pancrea. 2000;21:52–6.

    Article  CAS  Google Scholar 

  21. Brew R, Erikson JS, West DC, Kinsella AR, Slavin J, Christmas SE. Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine. 2000;12:78–85.

    Article  CAS  PubMed  Google Scholar 

  22. Lang K, Niggemann B, Zanker KS, Entschladen F. Signal processing in migrating t24 human bladder carcinoma cells: role of the autocrine interleukin-8 loop. Int J Cancer. 2002;99:673–80.

    Article  CAS  PubMed  Google Scholar 

  23. Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, Pettigrew J. Hif-1 and nf-kappab-mediated upregulation of cxcr1 and cxcr2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene. 2007;26:7333–45.

    Article  CAS  PubMed  Google Scholar 

  24. Rubie C, Frick VO, Pfeil S, Wagner M, Kollmar O, Kopp B, et al. Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer. World J Gastroenterol. 2007;13(37):4996–5002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. An H, Zhu Y, Xie H, Liu Y, Liu W, Fu Q, Ye D, Xu J. Increased expression of interleukin-8 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma. Tumour Biol. 2015.

  26. Lurje G, Husain H, Power DG, Yang D, Groshen S, Pohl A, et al. Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Ann Oncol. 2010;21(1):78–86. doi:10.1093/annonc/mdp280.

  27. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res. 2008;14:7554–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Ning Y, Manegold PC, Hong YK. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer. 2011;128(9):2038–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Baier PK, Eggstein S, Wolff-Vorbeck G, Baumgartner U, Hopt UT. Chemokines in human colorectal carcinoma. Anticancer Res. 2005;25:3581–4.

    CAS  PubMed  Google Scholar 

  30. Terada H, Urano T, Konno H. Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer. Eur Surg Res. 2005;37:166–72.

    Article  CAS  PubMed  Google Scholar 

  31. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol. 2003;170:3369–76.

    Article  CAS  PubMed  Google Scholar 

  32. Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez C, Yang XD. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappab. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9:3167–75.

    CAS  Google Scholar 

  33. Balbay MD, Pettaway CA, Kuniyasu H, Inoue K, Ramirez E, Li E, et al. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin Cancer Res. 1999;5:783–9.

    CAS  PubMed  Google Scholar 

  34. Schadendorf D, Fichtner I, Makki A, Alijagic S, Kupper M, Mrowietz U, et al. Metastatic potential of human melanoma cells in nude mice–characterisation of phenotype, cytokine secretion and tumour-associated antigens. Br J Cancer. 1996;74:194–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Lin Y, Xu J, Su H, Zhong W, Yuan Y, Yu Z, et al. Interleukin-17 is a favorable prognostic marker for colorectal cancer. Clin Transl Oncol. 2015;17(1):50–6.

    Article  CAS  PubMed  Google Scholar 

  36. Petanidis S, Anestakis D, Argyraki M, Hadzopoulou-Cladaras M, Salifoglou A. Differential expression of il-17, 22 and 23 in the progression of colorectal cancer in patients with k-ras mutation: ras signal inhibition and crosstalk with GM-CSF and IFN-gamma. PLoS One. 2013;8, e73616.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun. 2011;407:348–54.

    Article  CAS  PubMed  Google Scholar 

  38. Le Gouvello S, Bastuji-Garin S. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut. 2008;57:772–9.

    Article  PubMed  Google Scholar 

  39. Steiner GE, Newman ME, Paikl D. Expression and function of proinflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 2003;56:171–82.

    Article  CAS  PubMed  Google Scholar 

  40. Chen X, Wan J, Liu J. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer. 2010;69:348–354.7.

    Article  PubMed  Google Scholar 

  41. Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF. Generation and regulation of human CD4 + IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A. 2008;105:15505–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Lorestan University of Medical Sciences, Khorramabad, Iran

    Mohsen Mohammadi

  2. Department of Biology, Jundishapur University of Medical Sciences, Ahvaz, Iran

    Maria Kaghazian

  3. Department of Pathology, Be’sat Hospital, AJA University of Medical Sciences, Tehran, Iran

    Omid Rahmani & Katayoun Ziari

  4. Department of Emergency Medicine, Alborz University of Medical Sciences, Karaj, Iran

    Koorosh Ahmadi

  5. Department of Pathology, Loghman Hakim Hospital, Sarakhs, Iran

    Elham Hatami

  6. Department of Surgery, AJA University of Medical Sciences, Tehran, Iran

    Amir Talebreza

Authors
  1. Mohsen Mohammadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Kaghazian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Omid Rahmani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Koorosh Ahmadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elham Hatami
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Katayoun Ziari
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Amir Talebreza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amir Talebreza.

Ethics declarations

Conflicts of interest

None

Additional information

This article has been retracted at the request of the Editor-in-Chief, the International Society of Oncology and BioMarkers (ISOBM) and the Publisher per the Committee on Publication Ethics guidelines. The article shows evidence of irregularities in authorship during the submission process, and there is strong reason to believe that the peer review process was compromised. As such the validity of the content of this article cannot be verified.

An erratum to this article is available at http://dx.doi.org/10.1007/s13277-016-5483-2.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohammadi, M., Kaghazian, M., Rahmani, O. et al. RETRACTED ARTICLE: Overexpression of interleukins IL-17 and IL-8 with poor prognosis in colorectal cancer induces metastasis. Tumor Biol. 37, 7501–7505 (2016). https://doi.org/10.1007/s13277-015-4628-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4628-z

Keywords

Search

Navigation